Technology
Health
Biotechnology

Accelerate Diagnostics

$19.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-1.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AXDX and other stocks, options, ETFs, and crypto commission-free!

About

Accelerate Diagnostics, Inc. Common Stock, also called Accelerate Diagnostics, is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Read More It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.

Employees
287
Headquarters
Tucson, Arizona
Founded
1982
Market Cap
1.04B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
286.35K
High Today
$19.26
Low Today
$18.83
Open Price
$19.15
Volume
82.20K
52 Week High
$24.75
52 Week Low
$10.23

Collections

Technology
Health
Biotechnology
Healthcare
US
North America

News

Yahoo FinanceMay 9

Accelerate Diagnostics Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

19
PR NewswireMay 9

Accelerate Diagnostics Reports First Quarter 2019 Financial Results

TUCSON, Ariz., May 9, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter ended March 31, 2019. "We are pleased with our continued momentum in the first quarter, as we achieved strong consumable test kit revenue growth, along with a six-fold increase in commercial placements compared to the first quarter of 2018," said Lawrence Mehren, president and CEO of Accelerate Diagnostics, Inc. "During the quarter, we also began pre-clinical testin...

18
Yahoo FinanceMay 8

Did Hedge Funds Drop The Ball On Accelerate Diagnostics Inc (AXDX) ?

"Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back at all-time highs before we know it. I remain focused on preserving and growing our capital, and continue to believe that the best way to do so is via a value-driven, concentrate...

24

Earnings

-$0.42
-$0.37
-$0.32
-$0.27
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.41 per share
Actual
-$0.40 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.